Optio attends the Huntington Study Group annual meeting – November 2019, Sacramento, CA

Optio, a leader in strategic commercial services to rare disease pharmaceutical companies, has conducted work for the Huntington’s disease market for more than a decade. The 2020 HSG meeting conveyed the advancement of multiple promising therapies with differing mechanisms engendering a level of hope not seen since the the precise nature of the HD-associated mutation in HTT was elucidated in 1993. Optio continues its longstanding commitment to excellence in commercial planning and market research on behalf clients in the HD market.



Leave a Reply